ArriVent BioPharma, Inc. (AVBP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 31.54 |
| Open | 31.49 |
| Day High | 33.01 |
| Day Low | 30.83 |
| 52-Week High | 35.83 |
| 52-Week Low | 16.1 |
| Volume | 474,965 |
| Average Volume | 552,937 |
| Market Cap | 1.48B |
| PE | -9.14 |
| EPS | -3.47 |
| Moving Average 50 Days | 31.02 |
| Moving Average 200 Days | 25.08 |
| Change | 0.19 |
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
GlobeNewswire Inc.
Dec 22, 2025 1:00 PM GMT
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support potential accelerated and full regulatory appro
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
GlobeNewswire Inc.
Sep 22, 2025 8:05 PM GMT
NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today ann
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
GlobeNewswire Inc.
Sep 09, 2025 12:00 PM GMT
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed overall response rate (cORR) 68.2% and duration of response (DOR) 14.6 months by BICR in first-